指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

CAR-T细胞治疗后细胞因子释放综合征与巨噬细胞活化综合征的管理:SFGM-TC指南

[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].
指南 / 共识 · Bull Cancer · 2021-12-08
一句话结论SFGM-TC指南:托珠单抗和糖皮质激素仍是CAR-T后CRS治疗基石,托珠单抗/激素抵抗且伴噬血标志物(铁蛋白>10,000ng/mL等)提示CRS/MAS重叠,大剂量静脉阿那白滞素和激素为基础,晚期难治阶段用依托泊苷化疗,需与ICU密切协作。

CAR-T细胞已获批用于多种复发/难治B细胞恶性肿瘤,其特异性毒性如细胞因子释放综合征(CRS)的管理趋于明确。法语骨髓移植与细胞治疗学会(SFGM-TC)第十二届实践协调研讨会工作组聚焦CAR-T后CRS患者管理,并专章讨论罕见但危及生命的巨噬细胞活化综合征(MAS)。除对症措施和预防性广谱抗生素外,托珠单抗和糖皮质激素仍是CRS治疗基石;托珠单抗/激素抵抗的CRS若伴噬血标志物(脾肝肿大、高铁蛋白血症>10,000ng/mL、低纤维蛋白原血症等),应指向CRS/MAS重叠,治疗以大剂量静脉阿那白滞素和糖皮质激素为基础,晚期难治阶段加用依托泊苷化疗。这些并发症需要与重症监护病房密切协作。

要点

  • 托珠单抗和糖皮质激素仍是CAR-T后CRS治疗的基石,同时给予对症措施和预防性广谱抗生素。
  • 托珠单抗/激素抵抗的CRS伴噬血标志物(脾肝肿大、铁蛋白>10,000ng/mL、低纤维蛋白原血症等)应指向CRS/MAS重叠。
  • CRS/MAS重叠的适配治疗以大剂量静脉阿那白滞素和糖皮质激素为基础,晚期难治阶段加用依托泊苷化疗。
  • CAR-T后CRS/MAS等并发症需要与重症监护病房密切协作。
  • MAS是CAR-T后罕见但危及生命的并发症,指南专章讨论其管理。

适用人群与场景

  • 接受CAR-T细胞治疗、用于复发/难治B细胞恶性肿瘤的患者
  • CAR-T细胞治疗后发生细胞因子释放综合征(CRS)的患者
  • CAR-T细胞治疗后发生巨噬细胞活化综合征(MAS)的患者

诊断标准与关键阈值

  • 托珠单抗/糖皮质激素抵抗的CRS若伴噬血细胞增多标志物(脾脏和肝脏肿大、高铁蛋白血症>10,000ng/mL、低纤维蛋白原血症等),应指向CRS/MAS重叠的诊断

处置流程与药物剂量

  • CRS治疗:除对症措施和预防性广谱抗生素外,托珠单抗和糖皮质激素仍是治疗的基石
  • CRS/MAS重叠:采用适配治疗,以大剂量静脉阿那白滞素和糖皮质激素为基础
  • 晚期难治阶段:加用依托泊苷化疗
  • 这些并发症需要与重症监护病房密切协作

红旗征与不能漏的情况

  • 托珠单抗/糖皮质激素抵抗的CRS伴噬血细胞增多标志物(脾脏和肝脏肿大、高铁蛋白血症>10,000ng/mL、低纤维蛋白原血症等)提示CRS/MAS重叠,需按CRS/MAS重叠调整治疗
  • MAS是CAR-T后罕见但危及生命的并发症

研究设计与关键结果

  • SFGM-TC第十二届实践协调研讨会工作组聚焦CAR-T后CRS患者的管理,并专章讨论CAR-T后MAS这一罕见但危及生命的并发症

证据类型、等级与局限

  • 证据类型:SFGM-TC实践协调研讨会指南
  • 局限:原文未报告局限性

对床旁实践的改变

  • CAR-T后CRS患者除对症措施和预防性广谱抗生素外,使用托珠单抗和糖皮质激素作为治疗基石
  • 托珠单抗/激素抵抗且伴噬血标志物的CRS应按CRS/MAS重叠处理,使用大剂量静脉阿那白滞素和糖皮质激素,晚期难治阶段加用依托泊苷化疗
  • CAR-T后CRS/MAS等并发症的管理需要与重症监护病房密切协作

指南或共识出处

  • 指南名称:CAR-T细胞治疗后细胞因子释放综合征与巨噬细胞活化综合征的管理:SFGM-TC指南(Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC)
  • 发布机构:法语骨髓移植与细胞治疗学会(SFGM-TC)
  • 发表期刊:Bull Cancer

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such as cytokine release syndrome (CRS), tends to be better understood and well-defined. During the twelfth edition of practice harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a working group focused its work on the management of patients developing CRS following CAR-T cell therapy. A special chapter has been allocated to macrophage activation syndrome (MAS), a rare but life-threatening complication post-CAR-T. In addition to symptomatic measures and preemptive broad-spectrum antibiotics, immunomodulators such as tocilizumab and corticosteroids remain the corner stone for the treatment of CRS. Tocilizumab/corticosteroids-resistant CRS associated with haemophagocytosis markers (spleen and liver enlargement, hyperferritinaemia>10,000ng/mL, hypofibrinogenemia…) should direct the diagnosis towards an overlapping CRS/MAS. An adapted treatment will be based on high-dose IV anakinra and corticosteroids and chemotherapy with etoposide at late refractory stages. These complications and others delignate the need of close collaboration with an intensive care unit.

来源:Bull Cancer,查看原文。版权归原作者所有。

参考来源

  1. Tudesq JJ, Yakoub-Agha M, Bay JO, et al. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]. Bull Cancer. 2021. PMID: 34895696. doi:10.1016/j.bulcan.2021.11.002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。